Advertisement

Tourette Syndrome

  • Elaine Shapiro
  • Arthur K. Shapiro

Abstract

In the last 15 years we have seen a remarkable increase in interest and knowledge about Tourette syndrome (TS). In the past TS was considered to be a rare illness, with a poor prognosis and intellectual and psychological deterioration. Recent findings, primarily from pharmacological treatment and biochemical, genetic, neurological, encephalographic, psychological studies, have advanced our understanding of TS.

Keywords

Tardive Dyskinesia Tourette Syndrome Soft Neurological Sign Tourette Syndrome Patient Tourette Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abuzzahab, F. S., and Anderson, F. O., 1973, Gilles de la Tourette’s syndrome: International registry. Minn. Med. 56: 492–496.PubMedGoogle Scholar
  2. American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., American Psychiatric Association Press, Washington, DC.Google Scholar
  3. Ang, L., Borison, R., Dysken, M., and Davis, J. M., 1982, Reduced excretion of MHPG in TS, in: Advances in Neurology, Gilles de la Tourette Syndrome, Vol. 35 ( A. J. Friedhoff and T. N. Chase, eds.), pp. 171–175, Raven Press, New York.Google Scholar
  4. Balthazar, K., 1956, Über das anatomische Substrat der generalisierten Tic-krankheit (maladie des tics, Gilles de la Tourette): Entwicklungshemmung des Corpus Striatum, Arch. Psychiatr. Nervenkr. 195: 531–549.CrossRefGoogle Scholar
  5. Barbeau, A., 1978, Emerging treatments: Replacement therapy with choline or lecithin in neurological diseases, J. Can. Sci. Neurol. 5: 157–160.Google Scholar
  6. Barbeau, A., 1980, Cholinergic treatment in the Tourette syndrome, N. Engl. J. Med. 302: 1310–1311.PubMedCrossRefGoogle Scholar
  7. Baron, M., Shapiro, E., Shapiro, A., and Rainer, J. D., 1981, Genetic analysis of Tourette syndrome suggesting major gene effect, Am. J. Hum. Genet. 33: 767–775.PubMedGoogle Scholar
  8. Bing, R., 1925, Ueber lokale muskelspasmen und Tics, Schweiz. Med. Wochenschr. 6: 993–997Google Scholar
  9. Bliss, J., edited by Cohen, D. J., and Freedman, D. X., 1980, Sensory experiences of Gilles de la Tourette syndrome, Arch. Gen. Psychiatry 37:1343–1347.PubMedCrossRefGoogle Scholar
  10. Borak, W., 1969, Przypadek encefalopatii Z tikami Tourette’a zespolem anankastycznym i impulsywymi tendencjami do Samovszkodzen, Psychiatr. Pol. 3: 111–114.PubMedGoogle Scholar
  11. Borison, R. L., Ang, L., Chang, S., Dysken, M., Comaty, J. E., and Davis, J. M., 1982, New pharmacological approaches in the treatment of Tourette syndrome, in: Advances in Neurology, Gilles de la Tourette Syndrome, Vol. 35 (A. J. Friedhoff and T. N. Chase, eds.), pp. 377–382, Raven Press, New York.Google Scholar
  12. Butler, I. J., Koslow, S. H., Seifert, W. E., Jr., Caprioli, R. M., and Singer, H. S., 1979, Biogenic amine metabolism in Tourette syndrome, Ann. Neurol. 6: 37–39.PubMedCrossRefGoogle Scholar
  13. Caine, E. D., Polinsky, R. J., Kartzinel, R., and Ebert, M. H., 1979, The trial use of clozapine for abnormal involuntary movement disorders, Am. J. Psychiatry 136: 317–320.PubMedGoogle Scholar
  14. Caparulo, B. K., Cohen, D. J., Rothman, S. L., Young, J. G., Katz, J. D., Shaywitz, S. E., and Shaywitz, B. A., 1981, Computed tomographic brain scanning in children with developmental neuropsychiatric disorders, J. Am. Acad. Child Psychiatry 20: 338–357.CrossRefGoogle Scholar
  15. Cohen, D. J., Shaywitz, B. A., Johnson, W. T., and Bowers, M., Jr., 1974, Biogenic amines in autistic and atypical children, Arch. Gen. Psychiatry 31: 845–853.PubMedCrossRefGoogle Scholar
  16. Cohen, D. J., Shaywitz, B. A., Caparulo, B., Young, J. G., and Bowers, M. B., Jr., 1978, Chronic, multiple tics of Gilles de la Tourette’s disease, Arch. Gen. Psychiatry 35: 245–250.PubMedCrossRefGoogle Scholar
  17. Cohen, D. J., Shaywitz, B. A., Young, J. G., Carbonari, C. M., Nathanson, J. A., Lieberman, D., Bowers, M. B., Jr., and Maas, J. W., 1979, Central biogenic amine metabolism in children with the syndrome of chronic multiple tics of Gilles de la Tourette, J. Am. Acad. Child Psychiatry 18: 320–341.CrossRefGoogle Scholar
  18. Cohen, D. J., Detlor, J., Young, J. G., and Shaywitz, B. A., 1980, Clonidine ameliorates Gilles de la Tourette syndrome, Arch. Gen. Psychiatry 37: 1350–1357.PubMedCrossRefGoogle Scholar
  19. Dewulf, A., and Van Bogaert, L., 1940, Etudes anatomo-cliniques de syndromes hypercinetiques complexes, Mschr. Psychiatr. Neurol. 104: 53–61.CrossRefGoogle Scholar
  20. Eldridge, R., Sweet, R., Lake, C. R., Ziegler, M., and Shapiro, A. K., 1977, Gilles de la Tourette’s syndrome: Clinical, genetic, psychologic and biochemical aspects in 21 selected families, Neurology (Minneap.) 27: 115–124.Google Scholar
  21. Friedhoff, A. J., 1982, Receptor maturation in pathogenesis and treatment of Tourette syndrome, in: Advances in Neurology, Gilles de la Tourette Syndrome, Vol. 35 ( A. J. Friedhoff and T. N. Chase, eds.), pp. 133–140, Raven Press, New York.Google Scholar
  22. Golden, G. S., 1977, The effect of central nervous system stimulants on Tourette syndrome, Ann. Neurol. 2: 69–70.PubMedCrossRefGoogle Scholar
  23. Gonce, M., and Barbeau, A., 1977, Seven cases of Gilles de la Tourette’s syndrome: Partial relief with clozepam: A pilot study, Can. J. Neurol. Sci. 4: 279–283.PubMedGoogle Scholar
  24. Han-bai, C., and Han-quin, L. F., 1983, Tourette syndrome report of 19 cases, Chinese Med. J. 96 (1): 45–50.Google Scholar
  25. Hanin, I., Merikangas, J. R., Merikangas, K. R., and Kopp, U., 1979, Red-cell choline and Gilles de la Tourette syndrome, N. Engl. J. Med. 301: 661–662.PubMedGoogle Scholar
  26. Icagnoli, T., and Kane, R., 1981, Neuropsychological functioning in Gilles de la Tourette’s syndrome, J. Clin. Neuropsychol. 3: 165–169.CrossRefGoogle Scholar
  27. Iverson, S. D., and Alpert, J. E., 1982, Functional organization of the dopamine system in normal and abnormal behavior, in: Advances in Neurology, Gilles de la Tourette Syndrome, Vol. 35 ( A. J. Friedhoff and T. N. Chase, eds.), pp. 69–76, Raven Press, New York.Google Scholar
  28. John, E. R., Karmel, B. Z., Corning, W. C., Easton, P., Brown, D., Ahn, H., John, M., Harmony, T., Prichep, L., Toro, A., Gerson, I., Bartlett, F., Thatcher, R., Kaye, H., Valdes, P., and Schwartz, E., 1977, Neurometrics, Science 196: 1393–1410.PubMedCrossRefGoogle Scholar
  29. Joschko, M., and Rourke, B., 1982, Neuropsychological dimensions of Tourette syndrome: Test-retest stability and implications for intervention, in: Advances in Neurology, Gilles de la Tour-ette Syndrome, Vol. 35 ( A. J. Friedhoff and T. N. Chase, eds.), pp. 297–304, Raven Press, New York.Google Scholar
  30. Kidd, K. K., Prusoff, B. A., and Cohen, D. J., 1980, The familial pattern of Tourette syndrome, Arch. Gen. Psychiatry 37: 1336–1339.PubMedCrossRefGoogle Scholar
  31. Lake, C. R., Ziegler, M. G., Eldridge, R., and Murphy, D. L., 1977, Catecholamine metabolism in Gilles de la Tourette’s syndrome, Am. J. Psychiatry 134: 257–260.PubMedGoogle Scholar
  32. Lowe, T. L. Cohen, D. J., Detlor, J., Kremenitzer, M. W., and Shaywitz, B. A., 1982, Stimulant medications precipitate Tourette’s syndrome, JAMA 247: 1168–1169.PubMedCrossRefGoogle Scholar
  33. Moldofsky, H., and Sandor, P., 1983, Lecithin in the treatment of Gilles de la Tourette’s syndrome, Am. J. Psychiatry 140: 1627–1629.PubMedGoogle Scholar
  34. Morselli, P. L., Bianchetti, G., Durand, G., Le Heuzey, M. D., Zarifian, E. and Dugas, M., 1979, Haloperidol plasma level monitoring in pediatric patients, Ther. Drug Monit. 1: 35–46.PubMedCrossRefGoogle Scholar
  35. Nomura, Y., and Segawa, M., 1979, Gilles de la Tourette syndrome in Oriental children, Brain Dev. 1: 1103–111.CrossRefGoogle Scholar
  36. Obeso, J. A., Rothwell, J. C., and Marsden, C., 1981, Simple tics in Gilles de la Tourette syndrome are not prefaced by a normal premovement EEG potential, J. Neurol. Neurosurg. Psychiatry 44: 735–738.PubMedCrossRefGoogle Scholar
  37. Polinsky, R. J., Ebert, M. H., Caine, E. D., Ludlow, C., and Bassich, C. J., 1980, Cholinergic treatment in the Tourette syndrome, N. Engl. J. Med. 302: 1310.PubMedCrossRefGoogle Scholar
  38. Ross, M. S., and Moldofsky, H., 1978, A comparison of pimozide with haloperidol in Gilles de la Tourette syndrome, Am. J. Psychiatry 135: 585.PubMedGoogle Scholar
  39. Shapiro, A. K., and Shapiro, E., 1968, Treatment of Gilles de la Tourette’s syndrome with haloperidol, Br. J. Psychiatry 114: 345–350.PubMedCrossRefGoogle Scholar
  40. Shapiro, A. K., and Shapiro, E. S., 1980, Tics, Tourette Syndrome and Other Movement Disorders: A Pediatrician’s Guide, The Tourette Syndrome Association, Inc., Bayside, NY.Google Scholar
  41. Shapiro, A. K., and Shapiro, E., 198la, The treatment and etiology of tics and Tourette syndrome, Compr. Psychiatry 22(2):193–205.CrossRefGoogle Scholar
  42. Shapiro, A. K., and Shapiro, E., 1981b, Do stimulants provoke, cause or exacerbate tics and Tourette syndrome? Compr. Psychiatry 22 (3): 265–273.PubMedCrossRefGoogle Scholar
  43. Shapiro, A. K., and Shapiro, E., 1982a, Tourette syndrome: Clinical aspects, treatment and etiology, Semin. Neurol. 2 (4): 373–385.CrossRefGoogle Scholar
  44. Shapiro, A. K., and Shapiro, E., 1982b, An update on Tourette syndrome, Am. J. Psychother. 36: 379–390.PubMedGoogle Scholar
  45. Shapiro, A. K., and Shapiro, E., 1984, Controlled study of pimozide vs placebo in Tourette syndrome, J. Am. Acad. Child Psychiatry 23: 161–173.PubMedCrossRefGoogle Scholar
  46. Shapiro, E., and Shapiro, A. K., 1982, Tardive dyskinesia and chronic neuroleptic treatment of Tourette patients, in: Advances in Neurology, Gilles de la Tourette Syndrome, Vol. 35, ( A. J. Friedhoff and T. N. Chase, eds.), pp. 413, Raven Press, New York.Google Scholar
  47. Shapiro, A. K., Shapiro, E., and Wayne, H. L., 1973, Treatment of Gilles de la Tourette syndrome with haloperidol: Review of 34 cases, Arch. Gen. Psychiatry 28: 92–96.PubMedCrossRefGoogle Scholar
  48. Shapiro, A. K., Shapiro, E., Bruun, R. D., and Sweet, R. D., 1978, Gilles de la Tourette Syndrome, Raven Press, New York.Google Scholar
  49. Shapiro, A. K., Shapiro, E., and Sweet, R. D., 1981, Treatment of tics and Tourette syndrome, in: Disorders of Movement ( A. Barbeau, ed.), pp. 105–132, MTP Press, Ltd., Lancaster, England.Google Scholar
  50. Shapiro, A. K., Shapiro, E., and Eisenkraft, G. J., 1983a, Treatment of Tourette disorder with penfluridol, Compr. Psychiatry 24 (4): 327–331.PubMedCrossRefGoogle Scholar
  51. Shapiro, A. K., Shapiro, E., and Eisenkraft, G. J., 1983b, Treatment of Tourette disorder with pimozide, Am. J. Psychiatry 140 (9): 1183–1186.PubMedGoogle Scholar
  52. Shapiro, A. K., Baron, M., Shapiro, E., and Levitt, M., 1984, Enzyme activity in Tourette syndrome, Arch. Neurol. 41: 282–285.PubMedCrossRefGoogle Scholar
  53. Shapiro, A. K., Shapiro, E., and Eisenkraft, G. J., 1983c. Treatment of Tourette syndrome with clonidine and neuroleptics, Arch. Gen. Psychiatry 40: 1235–1240.PubMedCrossRefGoogle Scholar
  54. Shostak, M., and Perel, J., 1976, Radioimmunoassay for haloperidol, Fed. Proc. 35: 531, 1976.Google Scholar
  55. Singer, H. S., Tune, L. E., Butler, I. J., Zaczek, R., and Coyle, J. T., 1982, Clinical symptomatology, CSF neurotransmitter metabolites, and serum haloperidol levels in Tourette Syndrome, in: Advances in Neurology, Gilles de la Tourette Syndrome, Vol. 35 ( A. J. Friedhoff and T. N. Chase, eds.), pp. 177–183, Raven Press, New York.Google Scholar
  56. Stahl, S. M., and Berger, P. A., 1980, Cholinergic treatment in the Tourette syndrome, N. Engl. J. Med. 302: 1311.CrossRefGoogle Scholar
  57. Stahl, S. M., and Berger, P. A., 1981, Physostigmine in Tourette syndrome: Evidence for cholinergie underactivity, Am. J. Psychiatry 138: 240–242.PubMedCrossRefGoogle Scholar
  58. Sutherland, R. J., Kolb, B., Schoel, W. M., Whishaw, I. Q., and Davies, D., 1982, Neuro-psychological assessment of children and adults with Tourette syndrome: A comparison with learning disabilities and schizophrenia, in: Advances in Neurology, Gilles de la Tourette Syndrome, Vol. 35 ( A. J. Friedhoff and T. N. Chase, eds.), pp. 311–322, Raven Press, New York.Google Scholar
  59. Sweeney, D., Pickar, D., Redmond, D. E., Jr., and Maas, J., 1978, Noradrenergic and dopaminergic mechanisms in Gilles de la Tourette syndrome, Lancet 1: 872.PubMedCrossRefGoogle Scholar
  60. Tanner, C. M., Goetz, C. G., and Klawans, H. L., 1982, Cholinergic mechanisms in Tourette syndrome, Neurology (NY) 32 (11): 1315–1317.Google Scholar
  61. Tibbitts, R. W., 1981, Neuropsychiatric aspects of tics and spasms, Br. J. Hosp. Med. 25:454, 456–457, 459.Google Scholar
  62. Van Woert, M. H., Jutkowitz, R., Rosenbaum, D., and Bowers, M. B., Jr., 1976, Gilles de la Tourette syndrome: Biochemical approaches, in: The Basal Ganglia ( M. D. Yahr, ed.), pp. 459–465, Raven Press, New York.Google Scholar
  63. Wassman, E. R., Eldridge, R., Abuzzahab, S. S. R., and Nee, L., 1978, Gilles de la Tourettesyndrome: Clinical and genetic studies in a Midwestern city, Neurology (Minneap.) 28(3):304–307.Google Scholar
  64. Wilson, R. S., Garron, D. C., Tanner, C. M., and Klawans, H. L., 1982, Behavior disturbance in children with Tourette syndrome, in: Advances in Neurology, Gilles de la Tourette Syndrome, Vol. 35 ( A. J. Friedhoff and T. N. Chase, eds.), pp. 329–333, Raven Press, New York.Google Scholar
  65. Yeragani, V. K., Blackman, M., and Baker, G. H., 1983, Biological and psychological aspects of a case of Gilles de la Tourette syndrome, J . Clin. Psychiatry 44: 27–29.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1986

Authors and Affiliations

  • Elaine Shapiro
    • 1
  • Arthur K. Shapiro
    • 1
  1. 1.Tourette and Tic Laboratory and ClinicMount Sinai School of MedicineNew YorkUSA

Personalised recommendations